3. Umbruch 4.4..2005 - Online Pot

238 G.W. Guy and C.G. Stott
Figure 1. A glandular trichome from C. sativa L. (left) alongside a non-glandular trichome (right). The
head on the glandular trichome is the main site of cannabinoid biosynthesis.
• high inflorescence-to-leaf ratio (the harvest index);
• natural resistance to pests and diseases;
• sturdy growth capable of bulk plant handling;
• ease of harvesting;
• minimal production of anthers on female plants.
The production of uniform high-quality botanical raw material (BRM) of
defined composition is dependent upon the bulk production of cloned plants;
that is to say, all plants are derived from cuttings taken from a few select mother
plants. Being genetically identical, all the cloned plants have the potential
to replicate exactly the characteristics of the mother plant.
BRM is obtained from distinct varieties of C. sativa plant hybrids to maximize
the output of specific cannabinoids. The chemovars used are the result of
an extensive breeding programme spanning more than 15 years.
GW’s cannabis-based medicines are pharmaceutically formulated
whole-plant extracts of chemovars of C. sativa produced by selective breeding
to give a high content of defined cannabinoids, optimum habit and early flowering.
A wide range of chemovars of C. sativa has been selectively bred by
GW Pharmaceuticals. Each of these chemovars has a different cannabinoid
profile, and the chemovars have been specifically bred to produce the required